A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Idorsia Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: Daridorexant; Drug: Moxifloxacin

Study type: Interventional

Funder types: Industry

Identifiers

NCT04250506

ID-078-117

2019-003843-31 (EudraCT Number)

Details and patient eligibility

About

A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects

Enrollment: 36 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Signed informed consent in the local language prior to any study-mandated procedure.

• Czech citizen with the ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.

• Healthy male and female subjects aged 18 to 55 years (inclusive) at Screening.

• 12-lead safety ECG: QTcF < 450 ms for male subjects and < 470 ms for female subjects, QRS < 110 ms, and PR < 220 ms, and resting HR > 50 bpm and < 90 bpm with no clinically relevant abnormalities on 12-lead ECG after 5 min in the supine position at Screening and on Day 1 pre-dose of Period 1.

• Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.

• Women of childbearing potential are eligible only if the following applies:

  1. Negative serum pregnancy test at Screening.
  2. Negative serum pregnancy test on Day 1 of the first period.
  3. Agreement to consistently and correctly use a highly effective method of contraception with a failure rate of < 1% per year, be sexually inactive, or have a vasectomized partner from Screening up to at least 30 days after last study treatment administration in the last period with wash-out periods included. If a hormonal contraceptive is used, it must be initiated at least 1 month before first treatment administration.

• Women of non-childbearing potential must meet at least one of the following criteria:

  1. Previous bilateral salpingectomy, salpingo-oophorectomy, or hysterectomy.
  2. Premature ovarian failure confirmed by a specialist gynecologist.
  3. Post-menopausal, defined as 12 consecutive months with amenorrhea prior to Screening without alternative medical cause and confirmed with follicle-stimulating hormone (FSH) test.
  4. XY genotype.
  5. Turner syndrome.
  6. Uterine agenesis.

Exclusion criteria

• Pregnant or lactating women.
• Previous exposure to daridorexant.
• Known hypersensitivity to moxifloxacin or any of the drug product excipients or to other fluoroquinolone antibiotics.
• Any contraindication to moxifloxacin treatment.
• History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
• History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) or electrolyte disturbances, particularly hypokalemia.
• Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep disorders, restless legs syndrome, nightmare disorder, non-rapid eye movement sleep arousal disorders (sleep terror disorder or sleepwalking disorder), rapid eye movement sleep behavior disorder, circadian rhythm sleep-wake disorders.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

36 participants in 4 patient groups, including a placebo group

Treatment A: Daridorexant 50 mg

Experimental group

Description:

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Treatment:

Drug: Daridorexant

Treatment B: Daridorexant 200 mg

Experimental group

Description:

Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.

Treatment:

Drug: Daridorexant

Treatment C: Placebo

Placebo Comparator group

Description:

Placebo administered as tablets (4 x 50 mg) for oral use.

Treatment:

Drug: Placebo

Treatment D: Moxifloxacin 400 mg

Active Comparator group

Description:

Moxifloxacin administered as film-coated tablets for oral use.

Treatment:

Drug: Moxifloxacin